Eli Lilly reported that its combination treatment eloraTZP, combining an amylin receptor agonist with Zepbound, achieved 23.3% average weight loss in patients with obesity/overweight and type 2 diabetes, outperforming its triple-G candidate retatrutide in this population. At the highest dose, patients lost an average of 54.1 pounds over 48 weeks with improved blood sugar control, though gastrointestinal adverse events led to discontinuation in up to 27% of patients. Lilly plans to initiate phase 3 trials in late 2026.
Eli Lilly presented data at the EASD Annual Meeting in Milan showing that its eloraTZP combination therapy (amylin and Zepbound) achieved record weight loss results in patients with obesity and diabetes, outperforming other obesity treatments including Wegovy, Zepbound, CagriSema, and retatrutide.